Država: Europska Unija
Jezik: engleski
Izvor: EMA (European Medicines Agency)
cimicoxib
Vétoquinol SA
QM01AH93
cimicoxib
Dogs
Musculo-skeletal system
Relief of pain and inflammation associated with osteoarthritis.Management of peri-operative pain due to orthopaedic or soft-tissue surgeries.
Revision: 1
Authorised
2011-02-18
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET CIMALGEX 8 MG CHEWABLE TABLETS FOR DOGS CIMALGEX 30 MG CHEWABLE TABLETS FOR DOGS CIMALGEX 80 MG CHEWABLE TABLETS FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Vétoquinol SA Magny Vernois 70200 Lure France 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets for dogs Cimicoxib 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS Each tablet contains: Cimicoxib 8 mg Cimicoxib 30 mg Cimicoxib 80 mg Cimalgex 8 mg tablets are oblong, white to pale brown, with a break-line on both sides and can be divided into equal halves. Cimalgex 30 mg, tablets: oblong, white to pale brown, chewable tablets with 2 break-lines on both sides. The tablets can be divided into equal thirds. Cimalgex 80 mg, tablets: oblong, white to pale brown, chewable tablets with 3 break-lines on both sides. The tablets can be divided into equal quarters. 4. INDICATIONS For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri- operative pain due to orthopaedic or soft tissue surgery, in dogs. 5. CONTRAINDICATIONS Do not use in dogs less than 10 weeks of age. Do not use in dogs suffering from stomach or digestive system disorders or in dogs with bleeding problems. Do not use at the same time as corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use if the dog is hypersensitive to cimicoxib or any of the other ingredients in the product. Do not use in breeding, pregnant or lactating animals (see Section 12 “Special precautions for dogs”). 18 6. ADVERSE REACTIONS Mild gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported but these only lasted for a short time. On rare occasions, serious gastrointestinal problems such as bleeding and ulcer formation have occurred. Other adverse reactions incl Pročitajte cijeli dokument
1 ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Cimalgex 8 mg cimicoxib 8 mg Cimalgex 30 mg cimicoxib 30 mg Cimalgex 80 mg cimicoxib 80 mg For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablets. Cimalgex 8 mg, tablets: oblong, white to pale brown, chewable tablets with 1 break-line on both sides.The tablets can be divided into equal halves. Cimalgex 30 mg, tablets: oblong, white to pale brown, chewable tablets with 2 break-lines on both sides. The tablets can be divided into equal thirds. Cimalgex 80 mg, tablets: oblong, white to pale brown, chewable tablets with 3 break-lines on both sides. The tablets can be divided into equal quarters. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri- operative pain due to orthopaedic or soft tissue surgery, in dogs. 4.3 CONTRAINDICATIONS Do no use in dogs less than 10 weeks of age. Do not use in dogs suffering from gastrointestinal disorders or haemorrhagic disorders. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Refer also to section 4.8 Do not use in case of hypersensitivity to cimicoxib or to any of the excipients. Do not use in breeding, pregnant and lactating animals. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals 3 Since the safety of the medicinal product has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months. Use in animals suffering from impaired cardiac, renal or hepatic function, may involve additional risk. If such u Pročitajte cijeli dokument